Showing results (1-10 of 24) with videos related to
Sort By:
Pageof 3
Crohn'S & Colitis 360|February 13, 2023
Opioid Use in Patients With Inflammatory Bowel DiseaseXiwu Lin, Jennifer Lofland, Ling Zhang, et al.Alimentary Pharmacology & Therapeutics|July 16, 2025
Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative ColitisSilvio Danese, Rupert W Leong, Bruce E Sands, et al.Journal of Crohn'S & Colitis|March 9, 2019
Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic DataGeorge Philip, Freddy Cornillie, J Omoniyi Adedokun, et al.Journal of Crohn'S & Colitis|February 6, 2019
A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical TrialsKatherine Li, Richard Strauss, Colleen Marano, et al.The American Journal of Gastroenterology|March 31, 2011
Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitisGary Toedter, Katherine Li, Colleen Marano, et al.The Journal of Dermatology|June 12, 2010
Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parametersManjula Reddy, Gisela Torres, Thomas McCormick, et al.Clinical and Translational Gastroenterology|April 29, 2016
Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 YearPeter R Gibson, Brian G Feagan, William J Sandborn, et al.Gut|July 24, 2020
Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developmentsKlaus Gottlieb, Marco Daperno, Keith Usiskin, et al.Gastroenterology|August 28, 2020
Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative ColitisKatherine Li, Colleen Marano, Hongyan Zhang, et al.Inflammatory Bowel Diseases|July 9, 2018
Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With GolimumabWalter Reinisch, Jean-Frederic Colombel, Peter R Gibson, et al.Pageof 3